KIT and acute myeloid leukemia: Moreover, methotrexate, a central drug used in AML chemotherapy regimens, has been conjugated to a CD117 (a biomarker highly expressed on AML cells) specific aptamer, and the methotrexate-aptamer conjugate specifically inhibited AML cell growth and triggered cell apoptosis with little effect on CD117-negative cells49.